Advertisement
Original Study| Volume 22, ISSUE 12, P2547-2552, December 2021

Centrally Acting Anticholinergic Drugs Used for Urinary Conditions Associated with Worse Outcomes in Dementia

Published:August 30, 2021DOI:https://doi.org/10.1016/j.jamda.2021.08.011

      Abstract

      Objectives

      To investigate the associations between central anticholinergic burden and mortality, hospitalization, and cognitive impairment in people with dementia prescribed anticholinergic drugs for urinary symptoms.

      Design

      Retrospective cohort study.

      Setting and Participants

      Patients diagnosed with dementia receiving anticholinergic medication for bladder conditions (N = 540), assembled from a large healthcare database.

      Methods

      Central anticholinergic burden related to bladder drugs was estimated using the anticholinergic effect on cognition scale. Data were linked to national mortality and hospitalization data sources, and serially recorded Mini-Mental State Examination scores were used to investigate cognitive decline.

      Results

      Patients had a median survival of 4.1 years. Urinary drugs with a high anticholinergic effect on cognition score (tolterodine, oxybutynin) were associated with a 55% increased mortality risk (hazard ratio 1.55; 95% confidence interval 1.19‒2.01; P = .001) compared with drugs with low or no central anticholinergic burden (darifenacin, fesoterodine, trospium, mirabegron, solifenacin). Cognitive decline over a 24-month period around diagnosis was only detectable in the high central anticholinergic group, but there was no significant difference in cognitive trajectories between the high and low/no anticholinergic bladder drug groups. No increase of emergency hospitalization risk was seen in relation to central anticholinergic burden.

      Conclusions and Implications

      Urinary drugs with high central anticholinergic burden cause more harm than those acting peripherally and should be avoided in people with dementia. Further research is needed to test whether centrally acting anticholinergic agents in general cause worse outcomes in dementia.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Richardson K.
        • Fox C.
        • Maidment I.
        • et al.
        Anticholinergic drugs and risk of dementia: Case-control study.
        BMJ. 2018; 361: k1315
        • Coupland C.A.C.
        • Hill T.
        • Dening T.
        • et al.
        Anticholinergic drug exposure and the risk of dementia: A nested case-control study.
        JAMA Intern Med. 2019; 179: 1084-1093
        • Naples J.G.
        • Marcum Z.A.
        • Perera S.
        • et al.
        Concordance between anticholinergic burden scales.
        J Am Geriatr Soc. 2015; 63: 2120-2124
        • Welsh T.J.
        • van der Wardt V.
        • Ojo G.
        • et al.
        Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: A systematic review of reviews.
        Drugs Aging. 2018; 35: 523-538
        • Villalba-Moreno A.M.
        • Alfaro-Lara E.R.
        • Perez-Guerrero M.C.
        • et al.
        Systematic review on the use of anticholinergic scales in poly pathological patients.
        Arch Gerontol Geriatr. 2016; 62: 1-8
        • Bishara D.
        • Harwood D.
        • Sauer J.
        • Taylor D.M.
        Anticholinergic effect on cognition (AEC) of drugs commonly used in older people.
        Int J Geriatr Psychiatry. 2017; 32: 650-656
        • Bishara D.
        • Perera G.
        • Harwood D.
        • et al.
        The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis.
        Int J Geriatr Psychiatry. 2020; 35: 1069-1077
        • Chancellor M.B.
        • Staskin D.R.
        • Kay G.G.
        • et al.
        Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.
        Drugs Aging. 2012; 29: 259-273
        • Kay G.G.
        • Ebinger U.
        Preserving cognitive function for patients with overactive bladder: Evidence for a differential effect with darifenacin.
        Int J Clin Pract. 2008; 62: 1792-1800
        • Pagoria D.
        • O’Connor R.C.
        • Guralnick M.L.
        Antimuscarinic drugs: Review of the cognitive impact when used to treat overactive bladder in elderly patients.
        Curr Urol Reports. 2011; 12: 351-357
        • Stewart R.
        • Soremekun M.
        • Perera G.
        • et al.
        The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data.
        BMC Psychiatry. 2009; 9: 51
        • Perera G.
        • Broadbent M.
        • Callard F.
        • et al.
        Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource.
        BMJ Open. 2016; 6: e008721
        • World Health Organisation
        International Statistical Classifications of Diseases and Related Health Problems. 10th Revision.
        Instruction Manual. Vol 2. World Health Organisation, Geneva2010
        • Cunningham H.
        GATE, a general architecture for text engineering.
        Comput Hum. 2002; 36: 223-254
        • Mueller C.
        • John C.
        • Perera G.
        • et al.
        Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.
        Eur J Epidemiol. 2021; 36: 89-101
        • South London and Maudsley Biomedical Research Centre
        CRIS NLP SERVICE - Library of production-ready applications Version 15 [online].
        (Available at:)
        • Noble M.
        • McLennan D.
        • Wilkinson K.
        • et al.
        The English indices of deprivation 2007.
        2007
        • Folstein M.F.
        • Folstein S.E.
        • McHugh P.R.
        "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Royal College of Psychiatrists
        What is HoNOS?.
        (Avaialble at:)
        • Mueller C.
        • Perera G.
        • Hayes R.D.
        • et al.
        Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: A retrospective survival analysis.
        Age Ageing. 2018; 47: 88-94
        • Perera G.
        • Khondoker M.
        • Broadbent M.
        • et al.
        Factors associated with response to acetylcholinesterase inhibition in dementia: A cohort study from a secondary mental health care case register in london.
        PloS One. 2014; 9: e109484
        • Isik A.T.
        • Soysal P.
        • Stubbs B.
        • et al.
        Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: A meta-analysis and systematic review.
        J Am Geriatr Soc. 2018; 66: 1805-1811
        • Liang K.Y.
        • Zeger S.L.
        Longitudinal data analysis using generalized linear models.
        Biometrika. 1986; 73: 13-22
        • Oudshoorn K.
        • van Buuren S.
        • van Rijckevorsel J.
        Flexible multiple imputation by chained equations of the AVO-95 survey: TNO Prevention and Health TNO report PG/VGZ/99045 1999.
        • Rubin D.B.
        • Saczynski J.S.
        • Beiser A.
        • et al.
        • Multiple imputation for nonresponse in surveys
        John Wiley and Sons. 2010;
        • Peters M.E.
        • Schwartz S.
        • Han D.
        • et al.
        Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: The Cache County Dementia Progression Study.
        Am J Psychiatry. 2015; 172: 460-465
        • Hellström L.
        • Ekelund P.
        • Milsom I.
        • Skoog I.
        The influence of dementia on the prevalence of urinary and faecal incontinence in 85-year-old men and women.
        Arch Gerontol Geriatr. 1994; 19: 11-20
        • Uusvaara J.
        • Pitkala K.H.
        • Kautiainen H.
        • et al.
        Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients.
        Drugs Aging. 2011; 28: 131-138
        • Watanabe S.
        • Fukatsu T.
        • Kanemoto K.
        Risk of hospitalization associated with anticholinergic medication for patients with dementia.
        Psychogeriatrics. 2018; 18: 57-63
        • Shepherd H.
        • Livingston G.
        • Chan J.
        • Sommerlad A.
        Hospitalisation rates and predictors in people with dementia: a systematic review and meta-analysis.
        BMC Med. 2019; 17: 130
        • Mueller C.
        • Molokhia M.
        • Perera G.
        • et al.
        Polypharmacy in people with dementia: Associations with adverse health outcomes.
        Exp Gerontol. 2018; 106: 240-245
        • Fick D.M.
        • Semla T.P.
        American Geriatrics Society Beers Criteria: New year, new criteria, new perspective.
        J Am Geriatr Soc. 2012; 60: 614-615
        • Monroe T.
        • Carter M.
        Using the Folstein Mini-Mental State Exam (MMSE) to explore methodological issues in cognitive aging research.
        Eur J Ageing. 2012; 9: 265-274